Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13687980 | 0.80 | PARP1 (0.62) | PARP1CSNK2A1CSNK2A2CSNK2BNPC1 | |
| SCHEMBL10132645 | 0.80 | KDM4E (0.57) | PARP1CSNK2A1CSNK2A2CSNK2BNAMPT | |
| SCHEMBL10132650 | 0.80 | PARP1 (0.59) | PARP1CSNK2A1CSNK2A2CSNK2BROCK2 | |
| SCHEMBL10132633 | 0.79 | PARP1 (0.65) | PARP1CSNK2A1CSNK2A2CSNK2BNPC1 | |
| SCHEMBL10132620 | 0.79 | PARP1 (0.64) | PARP1CSNK2A1CSNK2A2CSNK2BNPC1 | |
| SCHEMBL10132659 | 0.78 | PARP1 (0.69) | PARP1CSNK2A1CSNK2A2CSNK2BKDM4E | |
| SCHEMBL10132586 | 0.77 | PARP1 (0.61) | PARP1CSNK2A1CSNK2A2CSNK2BKDM4E | |
| SCHEMBL10132625 | 0.77 | PARP1 (0.61) | PARP1CSNK2A1CSNK2A2CSNK2BKDM4E | |
| SCHEMBL13648691 | 0.77 | PARP1 (0.71) | PARP1CSNK2A1CSNK2A2CSNK2BIMPDH2 | |
| SCHEMBL10132584 | 0.77 | MAPT (0.58) | PARP1CSNK2A1CSNK2A2CSNK2BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110263581-A1 | FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263581-A1 | FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7956064-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-7956064-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20090264423-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264423-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| WO-2009108912-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263581-A1 | FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PARP1, PARP11, TNKS | PARP1 1/4885CSNK2A1 66/4885CSNK2A2 90/4885 |
| US-20090264423-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | PARP1 3/4885CSNK2A1 24/4885CSNK2A2 37/4885 |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | PARP1 690/4885CSNK2A1 680/4885CSNK2A2 810/4885 |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | PARP1 3/4885CSNK2A1 24/4885CSNK2A2 37/4885 |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | PARP1 690/4885CSNK2A1 680/4885CSNK2A2 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.